SCM
BIIB icon

Soleus Capital Management’s Biogen BIIB Stock Holding History

Soleus Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-72,800
Closed -$15.7M – 96
2024
Q1 		$15.7M Buy
+72,800
New +$17M 1.17% 27
2022
Q4 		– Sell
-23,200
Closed -$6.19M – 76
2022
Q3 		$6.19M Buy
+23,200
New +$4.93M 0.84% 38
2021
Q1 		– Sell
-3,899
Closed -$955K – 75
2020
Q4 		$955K Sell
3,899
-7,657
-66% -$1.98M 0.13% 53
2020
Q3 		$3.28M Buy
11,556
+9,256
+402% +$2.58M 1.74% 23
2020
Q2 		$615K Sell
2,300
-700
-23% -$210K 0.35% 52
2020
Q1 		$949K Sell
3,000
-4,500
-60% -$1.37M 1.1% 24
2019
Q4 		$2.23M Buy
+7,500
New +$2.08M 2.15% 17

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Soleus Capital Management's BIIB Position: Q2 2024 in Review

Soleus Capital Management sold out of Biogen (BIIB) in Q2 2024, closing a stake of 72,800 shares — an estimated $15.7M sold.

Soleus Capital Management first reported a position in BIIB in Q4 2019 and held it in 7 quarters. The position peaked at $15.7M in Q1 2024. 943 funds tracked by Wall St. Rank hold BIIB as of Q2 2024.

  • Soleus Capital Management reported no remaining Biogen position as of Q2 2024 after selling out during the quarter.
  • Soleus Capital Management sold 72,800 Biogen shares in Q2 2024, an estimated $15.7M.
  • Soleus Capital Management first reported a position in Biogen in Q4 2019 and held it in 7 quarters.
  • Soleus Capital Management's Biogen position peaked at $15.7M in Q1 2024.
  • 943 funds tracked by Wall St. Rank held Biogen as of Q2 2024.

Based on Soleus Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.